Literature DB >> 23707561

Cost-effectiveness and budget impact study of solvent/detergent (SD) treated plasma (octaplasLG®) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada.

Eline L Huisman1, Margreet C van Eerd2, J N Mario Ouwens2, Maria A de Peuter2.   

Abstract

The objectives of this study were to evaluate the cost-effectiveness and budget impact of octaplasLG(®) compared with fresh-frozen plasma (FFP) in all patients receiving a transfusion in Canada. A decision analytic framework was used to model acute and long-term complications that could follow plasma transfusion. Over a life time horizon, the cost with octaplasLG(®) were CA$612.91, which is CA$303.14 less than those with FFP. OctaplasLG(®) resulted in 0.021 quality adjusted life years (QALYs) gained in comparison with FFP. Because of higher efficacy and lower costs, octaplasLG(®) is expected to be the dominant treatment option over FFP in Canada.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Canada; Cost-effectiveness analysis; Fresh-frozen plasma; OctaplasLG(®); Transfusion

Mesh：

Substances：

Year:  2013        PMID： 23707561     DOI： 10.1016/j.transci.2013.04.045

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN： 1473-0502            Impact factor:   1.764


  5 in total

Review 1.  Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.

Authors:  Americo Cicchetti; Alexandra Berrino; Marina Casini; Paola Codella; Giuseppina Facco; Alessandra Fiore; Giuseppe Marano; Marco Marchetti; Emanuela Midolo; Roberta Minacori; Pietro Refolo; Federica Romano; Matteo Ruggeri; Dario Sacchini; Antonio G Spagnolo; Irene Urbina; Stefania Vaglio; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2016-07       Impact factor: 3.443

2.  Low incidence of hyperfibrinolysis and thromboembolism in 195 primary liver transplantations transfused with solvent/detergent-treated plasma.

Authors:  Håkon Haugaa; Eli Taraldsrud; Hans Christian Nyrerød; Tor Inge Tønnessen; Aksel Foss; Bjarte G Solheim
Journal:  Clin Med Res       Date:  2014-01-10

Review 3.  Establishing a bone marrow stromal cell transplant program at the National Institutes of Health Clinical Center.

Authors:  David F Stroncek; Marianna Sabatino; Jiaqiang Ren; Lee England; Sergei A Kuznetsov; Harvey G Klein; Pamela G Robey
Journal:  Tissue Eng Part B Rev       Date:  2014-02-07       Impact factor: 6.389

4.  Cost-effectiveness Analysis of Intraoperative Cell Salvage for Obstetric Hemorrhage.

Authors:  Grace Lim; Vladyslav Melnyk; Francesca L Facco; Jonathan H Waters; Kenneth J Smith
Journal:  Anesthesiology       Date:  2018-02       Impact factor: 7.892

5.  Solvent/detergent plasma: pharmaceutical characteristics and clinical experience.

Authors:  Giancarlo Maria Liumbruno; Massimo Franchini
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.